Journal Article

Validation of a New Homogeneous Immunoassay for the Detection of Carisoprodol in Urine

Guohong Wang, Kim Huynh, Rekha Barhate, Warren Rodrigues, Christine Moore, Cynthia Coulter, Michael Vincent and James Soares

in Journal of Analytical Toxicology

Volume 35, issue 2, pages 108-112
Published in print March 2011 | ISSN: 0146-4760
Published online March 2011 | e-ISSN: 1945-2403 | DOI:
Validation of a New Homogeneous Immunoassay for the Detection of Carisoprodol in Urine

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)


Show Summary Details


The objective of this project was to validate a new high-throughput homogeneous enzyme immunoassay (HEIA) for the rapid detection of carisoprodol in human urine. Carisoprodol (Soma®) and meprobamate are widely prescribed as musculoskeletal pain relief drugs and are listed as one of the 10 most frequently identified drugs associated with DUI cases. Carisoprodol has a short elimination half-life of 1–3 h; however, its major active metabolite, meprobamate, has a longer elimination half-life of 6–17 h. As a result, it is important for an immunoassay to cross-react with both compounds. The advantage of this new assay is that cutoff concentrations can be adjusted between 100 and 500 ng/mL. The reportable range was 25 to 1000 ng/mL for carisoprodol and 50 to 10,000 ng/mL for meprobamate. The intraday coefficient of variation (% CV) for the semi-quantitative assay was less than 1%. The homogeneous assay was validated with a total of 86 urine samples previously analyzed by liquid chromatography-tandem mass spectrometry with carisoprodol concentrations ranging from 50 to 10,000 ng/mL. The accuracy was found to be 100% when immunoassay cutoff concentrations of carisoprodol and meprobamate were set at 100 and 1000 ng/mL, respectively.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.